Matthew C.

K2 HealthVentures (K2HV) is an alternative investment firm that provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. We are healthcare specialists with deep domain expertise, and we understand both the opportunities and challenges that face venture-stage and growth-stage companies. Further, our flat organizational set-up enables nimble decision-making, and our evergreen fund structure allows us to be creative and adapt our facilities to a company’s specific needs over both the short and the long term. Over the last 4 years we have committed more than $1 billion in debt and equity capital to both private and public companies, and our team’s track record spans decades of investing in and supporting innovative life sciences and healthcare companies (with over $4 billion total investments in over 100 portfolio companies).

K2 HealthVentures (K2HV) is an alternative investment firm that provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. We are healthcare specialists with deep domain expertise, and we understand both the opportunities and challenges that face venture-stage and growth-stage companies. Further, our flat organizational set-up enables nimble decision-making, and our evergreen fund structure allows us to be creative and adapt our facilities to a company’s specific needs over both the short and the long term. Over the last 4 years we have committed more than $1 billion in debt and equity capital to both private and public companies, and our team’s track record spans decades of investing in and supporting innovative life sciences and healthcare companies (with over $4 billion total investments in over 100 portfolio companies).

Centre Partners, founded in 1986, is a longstanding and leading middle market private equity firm. With offices in New York and Los Angeles, we specialize in making control investments in North American based businesses primarily in the consumer, healthcare and business services industries.

As of September 30, 2024, Atalaya Capital Management was acquired by Blue Owl Capital. Across three asset classes – specialty finance, real estate, and corporate – Atalaya originates and opportunistically purchases credit or asset-based investments through closed-end funds for a client base of predominantly institutional investors, including endowments, foundations, sovereign wealth funds, and public and corporate pension plans. Atalaya’s funds target either a current yield or an absolute return, seeking to capitalize on our many years of experience across investment cycles and market conditions. Investment strategies often target investments in markets not well served by traditional lenders or the broader capital markets. Dyal Capital Partners owns a non-voting minority stake in Atalaya. Since inception, Atalaya has invested in excess of $14 billion.